Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Research Funding » EMD Serono, Pfizer, Broad Institute to Genomically Profile Lupus Patients

EMD Serono, Pfizer, Broad Institute to Genomically Profile Lupus Patients

Apr 02, 2014
|
staff reporter

NEW YORK (GenomeWeb News) – EMD Serono announced on Tuesday a research agreement with Pfizer and the Broad Institute to genomically profile systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients.

As part of the project, being funded jointly by EMD Serono and Pfizer, the Broad will use biochemical and next-generation sequencing technologies to investigate samples from SLE and LN patients, as well as analyze immune cell subpopulations, in order to identify biomarkers to better define patient populations for future therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Working Out the Effect

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Increased Genetic Privacy in Florida

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

Attention-Grabbing in Two Ways

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

Nature Papers Describe CRISPR Plant Editing Methods, DNA-PAINT Improvements, More

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.